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Abstract
West Nile virus (WNV) is a re-emerging pathogen that can cause fatal encephalitis. In mice, susceptibility to WNV has been
reported to result from a single point mutation in oas1b, which encodes 29–59 oligoadenylate synthetase 1b, a member of
the type I interferon-regulated OAS gene family involved in viral RNA degradation. In man, the human ortholog of oas1b
appears to be OAS1. The ‘A’ allele at SNP rs10774671 of OAS1 has previously been shown to alter splicing of OAS1 and to be
associated with reduced OAS activity in PBMCs. Here we show that the frequency of this hypofunctional allele is increased in
both symptomatic and asymptomatic WNV seroconverters (Caucasians from five US centers; total n=501; OR=1.6 [95% CI
1.2–2.0], P=0.0002 in a recessive genetic model). We then directly tested the effect of this SNP on viral replication in a novel
ex vivo model of WNV infection in primary human lymphoid tissue. Virus accumulation varied markedly among donors, and
was highest for individuals homozygous for the ‘A’ allele (P,0.0001). Together, these data identify OAS1 SNP rs10774671 as
a host genetic risk factor for initial infection with WNV in humans.
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Introduction
West Nile virus (WNV) is a re-emerging flavivirus transmitted
by mosquitoes to several species of birds. Humans and several
other mammalian species may be accidental dead-end hosts. First
isolated in Uganda from a febrile woman in 1937 [1], WNV has
caused sporadic outbreaks in the Middle East, Africa, Western
Asia, Europe, and Australia. In the Western Hemisphere, it was
first isolated from a patient during an outbreak of meningoen-
cephalitis in New York in 1999 [2,3,4]. Since then it has rapidly
spread across the United States into Canada and Central and
South America, and has caused annual outbreaks of disease.
Through November 18, 2008, there have been 28,906 US
laboratory-confirmed symptomatic WNV-seropositive cases re-
ported to the Centers for Disease Control and Prevention (CDC),
with 1121 (3.9%) WNV-induced deaths (www.cdc.gov). In
addition to human infections, the virus has caused significant
morbidity and mortality in birds and horses.
In the US, seroprevalence is ,3% in the general population and
20–30% of infected individuals have been estimated to become
symptomatic [5]. Clinical manifestations include West Nile fever
(WNF) and WNV-induced neuroinvasive disease (WNND), which
manifests primarily as meningitis and encephalitis [6]. To date, no
specific antiviral agents or vaccines have been approved by the
FDA for human WNV infection, and treatment is supportive.
Survivors of WNND may develop long-term neurologic sequelae.
Viral infections in man are typically controlled in part by early
induction of type I interferon (IFN), which initiates a cascade of
innate mechanisms that impair virtually all aspects of the viral life
cycle. Genetic studies in mice have identified several type I IFN-
regulated anti-viral effector pathways that control WNV replica-
tion, including the double-stranded RNA-dependent protein
kinase (PKR) mechanism of protein synthesis inhibition, and the
29–59 oligoadenylate synthetase (OAS) pathway of RNaseL-
mediated RNA degradation [7]. OAS enzymes catalyze the
synthesis of 29–59-linked oligoadenylates (2–5A) from ATP, which
can then bind and activate latent RNaseL resulting in the
degradation of host and viral RNAs [8].
Targeted gene disruption in mice has revealed a critical role for
the type I IFN Receptor, PKR and RNaseL for survival following
WNV infection [7,9]. A critical role for OAS emerged from
genetic analysis of the mouse locus flv, which determines in an
autosomal dominant manner susceptibility to WNV and other
flaviviruses [10,11]. Flv has recently been mapped by two groups
working independently [12,13] to a missense mutation in the 29–59
oligoadenylate synthetase 1b (oas1b) gene, which results in a
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been fully delineated. It clearly is not redundant with the multiple
other oas1 genes found in the mouse genome [14]. However, there
is evidence that protection may not actually be mediated through
RNase L [15], and it is not yet known whether the oas1b gene
product is enzymatically active [16]. The genetic data suggesting a
role for oas1b in protection against WNV in mice are supported by
in vitro experiments showing that WNV replication in cells
expressing wild-type oas1b is less efficient than in cells expressing
the truncated form [17,18]. Furthermore, genetic knock-in of the
resistant oas1b allele into a susceptible mouse strain resulted in
resistance to Yellow Fever Virus, a related flavivirus [19]. WNV
susceptibility has not been reported in this knock-in mouse. Taken
together, the combined in vivo and in vitro data suggest an important
role of oas1b in innate resistance to flavivirus infection in the
mouse.
Thus, we hypothesized that polymorphisms in the human
ortholog of oas1b, OAS1 [14], could influence outcome in humans
exposed to WNV. Established risk factors for human WNV disease
include age, immunosuppression, and genetic deficiency in the
chemokine receptor/HIV-1 coreceptor CCR5, due to homozygous
inheritance of the defective allele CCR5D32 [20,21]. Despite the
strong epidemiologic association with CCR5D32, only ,4% of
Caucasian symptomatic WNV-infected individuals can be ac-
counted for by CCR5 deficiency, indicating that other genetic risk
factors for WNV disease may exist. A small case-control study
(n=27 cases) failed to find evidence of association of severe WNV
disease with two OAS1 SNPs [22]. Instead, the investigators found
a strong association with a silent variant (rs3213545) in OAS-Like
(OASL), a paralogue of OAS1 located approximately 8 megabases
away that has not been found to encode a protein with OAS
activity [8]. In this report, we attempted to validate the OASL
association with WNV, but could not. Instead, we found a
consistent association of an OAS1 SNP and infection with WNV
from samples collected from five independent US centers, and
with WNV replication in human lymphoid tissue ex vivo.
Results
Structure and function of OAS1 SNP rs10774671
To investigate the role of the OAS system in controlling
outcome after WNV exposure in man, we scanned the OAS1 gene
for known polymorphisms that occur in this region. Unlike the
mouse genome, where 8 copies of oas1 have been identified (oas1a-
h), there is only one copy of OAS1 in the human genome, although
alternative splicing gives rise to several isoforms [14]. All OAS1
splice variants include exons 1–5, but vary with regard to
downstream exons, and thus produce proteins of various sizes,
including the p42, p44, p46, p48, and p52 forms [14,23]. We
identified common SNPs in the OAS1 gene region in the CEPH
cohort using data from the International HapMap Project (www.
hapmap.org). Human OAS1 is one of three genes in the OAS
cluster, ordered OAS1, OAS3 and OAS2 on chromosome 12 [24].
As shown in Figure 1, at least eleven SNPs in the OAS1 region
have been found to cluster into two blocks of linkage disequilib-
rium (LD). The first block contains four SNPs, three of which are
found within the first intron (rs7956880, rs10744785, and
rs4766662) and one of which (rs2158390) is found in the
59UTR. The second block contains seven SNPs, with rs3741981
in exon 3; rs2057778, rs2285934 and rs2285934 in intron 3;
rs10774671 located at the last nucleotide in intron 5; rs1051042
and rs2660 in exon 7; and rs7135577 in the 39UTR. The SNPs
found in block 1 are not in coding regions. The six SNPs in block 2
excluding rs3741981 are in tight LD (Figure 1, the black region in
block 2) and form two haplotypes that have been previously shown
by Bonnevie-Nielsen and colleagues to be highly associated with
the level of OAS enzymatic activity measured in peripheral blood
mononuclear cells [23]. These investigators concluded that
rs10774671 is most likely to be the functional SNP in this block
because it sits at the last nucleotide of intron 5 in the OAS1 gene
and serves as a splice acceptor site for exon 7. The G allele is
predicted to allow splicing to occur resulting in the production of a
p46 form with high enzymatic OAS activity. The A allele is
predicted to prevent splicing at this site; instead, splicing occurs
further downstream, resulting in two other forms, designated p48
and p52 associated with lower OAS enzymatic activity. Hetero-
zygotes were reported to have intermediate OAS activity [23].
Although other splice variants of this gene exist, including p42 and
p44, the splice variants that arise from the use of exon 7 (p46, p48,
and p52) are controlled by rs10774671 [23,24]. Thus, this
polymorphism is a biologically plausible genetic probe to
investigate the role of OAS1 in human WNV disease.
Study participants and genotype analysis of OAS1 SNP
rs10774671
To test whether this SNP is associated with WNV infection, we
obtained serum or plasma from five independent US sources of
Caucasian WNV+ individuals (n=501). We collected symptom-
atic WNV-seropositive patient samples (n=331) from the
following state public health departments and outbreak years:
Arizona (2004), California (2005), Colorado, (2003) and Illinois
(2005–6) as detailed in Table 1. These samples were from
individuals who sought medical attention and where WNV was
considered in the differential diagnosis because of compatible signs
and symptoms (fever, meningitis, encephalitis) and confirmed by
serologic testing. We also obtained asymptomatic WNV-seropos-
itive blood donor samples (n=170) from the American Red Cross
(ARC) national blood supply screening program, identified as
WNV nucleic acid amplification test (NAT) reactive and
confirmed by serologic testing. These individuals remained
Author Summary
When humans are exposed to infectious agents, the
outcome may vary: some remain uninfected, some who
become infected remain asymptomatic, and symptomatic
individuals may develop clinical manifestations that vary in
number and severity. Both host and environmental factors
are thought to influence outcome. Here we show that a
specific human mutation that results in reduced function
in a known antiviral gene named OAS1 is associated with
increased rate of infection with West Nile virus, a member
of the flavivirus family. OAS1 codes for a component of the
type I interferon signaling system; its homologue in mice
has been shown previously to be important for flavivirus
susceptibility. Individuals carrying two copies of the
hypofunctional variant of OAS1 were found more fre-
quently than expected among both asymptomatic and
symptomatic WNV-positive individuals. To investigate
further, we developed a novel model of WNV replication
using human tonsil tissue in which high variability in
replication was observed among donors. We found that
the highest virus accumulation occurred in donors with
two copies of the hypofunctional OAS1 variant. Together
these data suggest that OAS1 activity may influence the
probability of initial infection, but not the severity or
symptomatic quality of infection, after WNV exposure in
man.
OAS1 and Initial Infection with West Nile Virus
PLoS Pathogens | www.plospathogens.org 2 February 2009 | Volume 5 | Issue 2 | e1000321symptom-free, according to self-assessment in a follow-up
questionnaire, for at least 2 weeks post-donation [25,26].
For comparison, we obtained two groups of US Caucasian
control samples (n=552). The first was comprised of healthy US
Caucasian random blood donors (RBD) collected prior to the
introduction of WNV into the US in 1999 (n=360). The second
consisted of healthy US blood donors collected by the ARC who
were identified during routine blood screening as WNV false
positives (initial reactivity by WNV NAT that could not be
replicated and WNV-seronegative (n=192)).
We limited the analysis to self-reporting Caucasian individuals
because the allele frequency of the OAS1 rs10774671 SNP varies
according to race (www.ncbi.nlm.nih.gov/projects/SNP/). In
both cases and controls, the overall genotyping success rate was
.96.0%. 156 patient samples were re-tested using a second
genotyping method with 100% concordance. Within each group
(WNV+ and control), the OAS1 genotypes were in Hardy-
Weinberg equilibrium (HWE; p=0.51 and p=0.93, respectively).
In our control samples (n=552), the frequency of the OAS1
rs10774671 AA genotype shown in Table 1 (38.0%) was consistent
with the observed AA genotypic frequency in other published
Caucasian cohorts representing over 5000 individuals predomi-
nantly from Europe (36.8–41.1%) [27,28,29] as well as the
published report in the CEPH cohort in the HapMap Project
(39%, n=59; www.hapmap.org).
OAS1 rs10774671 AA genotype is elevated in WNV-
infected individuals
A genotypic contingency analysis (362) for OAS1 rs10774671
revealed a statistically significant association when WNV-positive
samples were compared to controls (p=0.0008). In our analysis,
we considered the dominant, recessive and additive genetic models
(Table 2), and all were statistically significant (p,0.05). Using the
recessive model when all cases were grouped together, the AA
genotype was significantly greater in WNV-positive subjects than
in controls (Odds Ratio (OR)=1.6 [95% Confidence Interval (CI)
1.3–2.1, p=0.0001; Table 2). A similar trend in OR was observed
in each of the 5 centers when considered separately, ranging
between 1.5 and 1.7. Analysis of the data using the additive model
also showed a highly significant association (OR=1.4 per allele
[95% CI 1.2–1.7], p=0.0003; Table 2) indicating that having
more A alleles was significantly greater in WNV-positive
individuals than in controls. The OR for each center when
considered separately was less consistent in this model, spanning
between 1.2 and 2.0. To determine which model fits the data best,
Figure 1. Haplotype block structure of the human OAS1 gene in the CEPH cohort. The location of rs10774671 (boxed) and the surrounding
SNPs in and around the OAS1 gene are shown. LD block structure of the OAS1 gene found in the CEPH cohort was analyzed using Haploview version
4.0. Pairwise r
2 values are scaled in gray with higher r
2 values shown in darker color; black indicates an r
2=1.
doi:10.1371/journal.ppat.1000321.g001
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of A allele under the three models (Figure 2A). Superimposed are
the observed proportions of WNV-positive individuals by copies of
A (square boxes) along with the 95% CI. By comparing the
observed to predicted proportion of cases by number of alleles
using chi-square goodness-of-fit tests, we determined that the
recessive and additive models are approximately equally supported
by the data, with the dominant model having a decidedly poorer
fit. We also analyzed each genotype separately, using GG as the
reference genotype, since the G allele is the ancestral allele (from
published Pan troglodytes sequence data, www.ncbi.nlm.nih.gov). As
shown in Figure 2B, the strongest association with WNV infection
was observed when AA was compared to the GG genotype
(OR=1.8, 95% [CI] 1.2–2.7, p=0.002). There was also a
statistically significant increase between the AG and AA genotypes
(OR=1.5 95% [CI] 1.2–2.0, p=0.002). The comparison between
the GG and AG genotypes was not statistically significant
(OR=1.2, 95% [CI] 0.8–1.7, p=0.38), suggesting a better fit
for the recessive model. Taken together, these data show that the
AA genotype of OAS1 at SNP 10774671 is significantly elevated in
individuals seropositive for WNV.
OAS1 rs10774671 AA genotype is associated with
infection and not severity of clinical outcome
We next asked whether the elevated frequency of the A allele in
WNV-seropositive subjects varied according to clinical outcome.
The AA genotypic frequency for the four groups of symptomatic
WNV+ subjects ranged between 47.1–51.1% (average 49.5%,
n=331). The AA genotypic frequency for asymptomatic WNV+
subjects from the ARC fell within this range at 48.8% (n=170). In
contrast, the AA frequency in the control samples was 38.0%
(n=552) (Figure 3A). Analysis of symptomatic patient samples for
whom clinical outcome data were available (n=294) showed a
similar distribution of OAS1 genotypes in both the WNF and
Table 1. Characteristics and genotypes of self-reporting Caucasian study subjects.
AZ WNV+ CO WNV+ CA WNV+ IL WNV+ ARC WNV+ Combined WNV+ ARC WNV2 RBD WNV2 Combined WNV2
Number 135 72 87 37 170 501 192 360 552
Mean age (y) 57618 50618 54618 54619 52615 53617 49615 55613
% Male sex 52.6 43.1 51.7 62.2 72.9 58.7 56.3 58.3 56.8
% WNF
a 36.3 22.2 62.1 – 0 36 – – –
% WNND
a 60 77.8 31 – 0 49.5 – – –
% Unspecified
a 3.7 0 6.9 100 0 14.5 – – –
% Mortality (n) 4.4 (6) 1.4 (1) 6.9 (6) – 0 4.4 (13)
b –––
% OAS1 AA (n) 51.1 (69) 48.6 (35) 47.1 (41) 51.4 (19) 48.8 (83) 49.3 (247) 40.6 (78) 36.7 (132) 38.0 (210)
% OAS1 AG (n) 38.5 (52) 44.4 (32) 35.7 (31) 48.6 (18) 38.2 (65) 39.5 (198) 46.2 (89) 46.4 (167) 46.4 (256)
% OAS1 GG (n) 10.4 (14) 6.9 (5) 17.2 (15) 0.0 (0) 12.9 (22) 11.2 (56) 13.0 (25) 16.9 (61) 15.6 (86)
% OAS-Like TT (n) 6.7 (9) 15.3 (11) 6.9 (6) 10.8 (4) 10.6 (18) 9.6 (48) 12.0 (23) 8.9 (32) 10.0 (59)
% OAS-Like CT (n) 44.4 (60) 44.4 (32) 39.1 (34) 56.8 (21) 40.0 (68) 42.9 (215) 41.7 (80) 41.9 (151) 41.8 (245)
% OAS-Like CC (n) 48.9 (66) 40.3 (29) 54.0 (47) 32.4 (12) 49.4 (84) 47.5 (238) 46.4 (89) 49.2 (177) 48.2 (281)
aCases from US states were classified into either West Nile fever (WNF), West Nile neuroinvasive disease (WNND), or unspecified disease categories by physician
interview. All samples from ARC experienced no symptoms as assessed by questionnaire $2 weeks post-donation.
bMortality data do not include Illinois for which clinical outcome was not provided. RBD, random blood donors; AZ, Arizona; CO, Colorado; CA, California; IL, Illinois; ARC,
American Red Cross; WNV+, WNV-seropositive individuals; WNV2, WNV-seronegative controls. All groups were in Hardy-Weinberg equilibrium. Genotypic frequencies
where the total does not equal 100.0% are due to rounding imprecision.
doi:10.1371/journal.ppat.1000321.t001
Table 2. OAS1 rs10774671 is associated with increased risk of WNV infection.
Number Additive Model Recessive Model Dominant Model
OR 95% CI P OR 95% CI P OR 95% CI P
All WNV+ 501 1.4 1.2–1.6 0.0003 1.6 1.2–2.0 0.0002 1.5 1.0–2.1 0.04
Arizona 135 1.5 1.2–1.9 0.007 1.7 1.2–2.5 0.006 1.6 0.88–2.9 0.12
Colorado 72 1.5 1.1–2.1 0.03 1.5 0.94–2.5 0.08 2.5 0.97–6.3 0.05
California 87 1.2 0.9–1.6 0.36 1.5 0.92–2.3 0.11 0.88 0.49–1.6 0.69
Illinois 37 2 1.2–3.1 0.02 1.7 0.90–3.4 0.11 ** ** 0.003*
ARC 170 1.3 1.0–1.7 0.03 1.6 1.1–2.2 0.01 1.2 0.75–2.1 0.4
OR, odds ratio; CI, confidence interval; ARC, American Red Cross. Values were calculated in comparison to the genotype frequency in 552 healthy North American
Caucasian WNV-seronegative control samples. Genetic models assume the ancestral G allele as the reference allele. Recessive, GG and GA genotypes combined;
Dominant, GA and AA genotypes combined; Additive, GG versus AG and AG versus AA. ORs calculated using JMP software.
*p value calculated using Fisher’s exact test.
**OR is infinite.
doi:10.1371/journal.ppat.1000321.t002
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to death as an outcome, the sample size is underpowered for
analysis: only 13 of all 294 cases for which clinical outcome data
were available experienced fatal WNV infection. These data are
most consistent with the hypothesis that OAS1 at SNP 10774671 is
a risk factor for seroconversion after exposure to WNV, but not for
specific clinical manifestations.
OAS1 SNP rs10774671 is independentof CCR5D32 and age
We previously demonstrated that CCR5D32 homozygosity is a
strong risk factor for symptomatic WNV disease [20,21]. To
investigate whether the association of OAS1 SNP 10774671 with
WNV infection is independent of CCR5D32, we analyzed the
distribution of OAS1 in WNV+ subjects from the four groups of
symptomatic US Caucasians who were CCR5+/+ (n=261),
CCR5+/D32 heterozygotes (n=53), and CCR5D32/D32 homozy-
gotes (n=17). The expected frequencies were calculated solely on
OAS1 HWE considerations, since the increase in CCR5D32
homozygotes resulted in skewing of HWE for this allele, as
previously reported [20,21]. The distribution of OAS1 genotypes
according to CCR5 genotype did not differ significantly from
expectation as shown in Table S1 (x
2=5.2, p=0.26) suggesting
that these alleles assort independently.
Since age is also an accepted risk factor for symptomatic WNV
infection, we determined OAS1 SNP 10774671 genotypes in all
symptomatic WNV+ subjects stratified by age; ,45 years old
(n=99), between 45 and 64 years old (n=131), and .64 years old
(n=101) as shown in Table S2, but found no significant
differences.
Lack of OASL SNP rs3213545 association with
symptomatic WNV disease
We next attempted to validate the association previously
identified by Yakub et al. between OASL SNP rs3213545 and
WNV infection [22]. Contingency analysis (362) did not reveal
any significant association (p=0.93) when the WNV-infected
seropositive subjects (n=501) were compared to WNV-sero-
negative controls (n=552). Analysis of the additive model
(OR=1.0 [95%CI 0.8–1.3], p=0.94), the recessive model
(OR=1.0, [95%CI 0.69–1.6], p=0.83), and the dominant
model (OR=1.0, [95%CI 0.8–1.3], p=0.82) revealed no
association with WNV infection (Table S3). When samples
collected from each of the 5 centers were analyzed separately,
no significant association was found (Table S3). The frequency
of TT homozygosity was not elevated above controls (Figure 3B)
and did not vary between asymptomatic donors and symptom-
atic patients. Since the previous study by Yakub et al. showed an
association between this SNP and severe WNV disease, we also
looked for an association according to clinical outcome. As
shown in Table 3 and Figure 3B, no association was found with
either WNF or WNND, the more severe CDC clinical
definition.
Development of an ex vivo model for WNV replication in
human lymphoid tissue
To directly assess the role of OAS1 during active WNV
replication in human cells, we developed an experimental ex vivo
model of WNV infection using explants of human tonsil tissue. This
model may mimic the early events after infection that may occur in
vivo in the draining lymph node, shown in mice to be an early site of
viral replication that precedes CNS spread [30]. Since infection in
primary human cells in vitro typically requires exogenous stimulation
or activation [31,32], this system is more natural in that the
architecture and composition of the primary lymphoid tissue are
preserved and no exogenous stimuli are added. Explanted tissue
from patients undergoing tonsillectomies was sectioned and
inoculated with WNV. For each experimental condition, 27 blocks
of tissue were sectioned per donor to control for variation in the
number of susceptible cells that may occur between individual slices
of tissue from the same donor. Supernatant from the cultured tissue
was tested every third day for virus using a focus forming unit (FFU)
assay. As shown in Figure 4A, virus was detected in the culture
supernatant at the earliest time point (day 3) and increased
throughout the 12 day culture for each of the 21 donors tested.
WNV-infected cells were visible by direct immunostaining of the
tissues (Figure 4B). Tonsils from all donors supported WNV
replication to high levels that varied widely among donors,
particularly at early time points post-infection (e.g. greater than 4
Figure 2. OAS1 allele dosage effect on risk of WNV infection. (A)
A plot of the estimated probabilities of being WNV-positive as a
function of the number of copies of rs10774671 A allele under three
different genetic models. The solid line is the additive model; the
dotted line is the recessive model; the dashed line is the dominant
model. Also graphed are the observed proportions of WNV cases (solid
squares) along with 95% CI (solid vertical lines). (B) The allele dosage
effect of the A allele for SNP rs10774671 was examined using GG
homozygous individuals as a reference genotype. OR (bars) were
calculated, and 95% CI shown (lines) were determined for all study
subjects. Chi-square test was used to calculate P values (shown).
doi:10.1371/journal.ppat.1000321.g002
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investigating WNV pathogenesis but also for testing the efficacy of
potential WNV therapeutics.
Early WNV replication may be regulated by OAS1
genotype
The variation in virus production we observed among donors
provided an ideal opportunity to test the dependence of viral
replication on OAS1 genotype in intact human tissue, assuming
that OAS1 mRNA was expressed in the tissue. Twelve of the 21
tissues tested for WNV replication were available for RNA
extraction to investigate this. First we examined the effect of
WNV infection on expression of all OAS1 transcripts (Figure 5A),
using primers located between exons 2 and 3. OAS1 mRNA was
detected in uninfected tissue from all 12 donors (data not shown),
and expression of total OAS1 mRNA was induced ,2 fold by
WNV compared with donor-matched uninfected control tissue at
day 3 post-infection (p=0.01; Figure 5A). This increased to ,4.6
fold induction for both day 6 (p=0.002)andday12(p,0.0001)
after infection. Since OAS1 is an IFN-stimulated gene, we also
measured IFNb1 in these samples and observed a significant
increase above control at day 6 (p=0.002) and day 12 (p=0.007)
post infection (Figure 5B). These 12 samples were also tested by
RT-PCR for OAS1 rs10774671 A and G allele-specific
transcripts using a previously established method [23]. Both A
and G allele-specific transcripts (319 and 417 bp amplicons for A
allele; 416 bp amplicon for G allele) were detected in appropriate
uninfected tissue from all 12 donors (Figure 5C). As shown in
Figure 5D, total OAS1 SNP rs10774671-specific mRNA modestly
increased in a time-dependent manner after infection. This was
due at least in part to induction of OAS1 SNP rs10774671 A
allele-specific RNA, as shown by analysis of tissue from AA
homozygotes (n=5; Figure 5E). Since RNA generated from the A
and G alleles differ by only 1 nucleotide, we were unable to
quantitate the relative induction of A and G allele-specific RNA
in WNV-infected tissue from AG heterozygotes. We observed
,1.5-fold induction of G allele-specific mRNA in infected tissue
from the one GG homozygote that was available. Thus both
Figure 3. OAS1 rs10774671 AA genotype frequency is elevated in both symptomatic and asymptomatic WNV-seropositive subjects.
(A) A plot of the OAS1 rs10774671 AA genotypic frequency in all WNV-positive samples (n=501), WNV-positive samples from individuals who
remained symptom-free (asymptomatic; n=170), and WNV-positive samples from individuals who experienced symptomatic disease (n=331).
Symptomatic WNV-seropositive cases were further examined based on the CDC-defined clinical definition of WNF (n=119) or WNND (n=164). Black
bar and the dotted line indicate the genotypic frequency of the control population (n=552). (B) A similar analysis was performed for the OASL
rs3213545 TT genotype.
doi:10.1371/journal.ppat.1000321.g003
Table 3. Distribution of OAS1 (rs10774671) and OAS-Like (rs3213545) genotypes as a function of clinical outcome in symptomatic
WNV-seropositive patients.
OAS1 AA OAS1 AG OAS1 GG OAS-Like TT OAS-Like CT OAS-Like CC
WNF
a 62 (52.1) 40 (33.6) 17 (14.3) 6 (5.0) 51 (42.9) 62 (52.1)
WNND
a 77 (47.0) 71 (43.3) 16 (9.7) 18 (11.0) 71 (43.3) 75 (45.7)
Not Specified
a 6 (54.5) 4 (36.4) 1 (9.1) 2 (18.2) 4 (36.4) 5 (45.4)
Death 4 (30.8) 4 (30.8) 5 (38.4) 1 (7.7) 3 (23.1) 9 (69.2)
Total 145 (49.3) 115 (39.1) 34 (11.6) 26 (8.8) 126 (42.9) 142 (48.3)
aPatients were classified into either West Nile fever (WNF), West Nile neuroinvasive disease (WNND), or unspecified disease categories by physician interview. Data do
not include the Illinois cases for which no clinical outcome information was provided. No statistically significant differences were observed comparing the genotype
frequencies of WNF versus WNND. With regard to death as an outcome, the sample size is underpowered for analysis.
doi:10.1371/journal.ppat.1000321.t003
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RNA level throughout the course of WNV infection of human
tonsil tissue, allowing us to ask whether virus replication in this
system is OAS1 genotype-dependent.
To test whether OAS1 variation affects WNV infection in
human lymphoid tissue ex vivo, we genotyped patient samples for
the OAS1 rs10774671 SNP. Of the 21 donors tested, 7 were
homozygous for the A allele (33.3%), 2 were homozygous for the
G allele (9.5%), and the remaining 12 were AG heterozygotes
(57.2%). This distribution is similar to the genotypic distribution
observed in controls. When viral production was analyzed as a
function of OAS1 genotype, we found that tissues from individuals
homozygous for the A allele supported higher levels than tissues
from patients with AG or GG genotypes (Figure 6). The most
significant difference was observed 3 days post infection
(p,0.0001) with a mean viral titer of 3.9610
4 ffu in tissues from
donors with the AA genotype versus those from individuals who
were either AG or GG (1.1610
3 ffu). At day 6, the mean viral titer
was still greater in AA than in non-AA tissues (1.7610
6 versus
5.0610
4 ffu, respectively; p=0.002). At day 9, the differences in
viral titer had decreased (1.3610
6 ffu for AA versus 3.8610
5 ffu for
non-AA; p=0.02). By day 12 post-infection, no significant
difference was observed (p=0.80). Thus the allele associated with
higher OAS enzymatic activity (G) is associated with lower viral
production for at least 75% of the period of observation after
infection in lymphoid tissue.
Discussion
The present study provides the first evidence in support of the
hypothesis that OAS1 influences risk of infection in response to
WNV exposure in humans. This is based on association of the
OAS1 ‘A’ allele at SNP rs10774671, which has previously been
associated with low OAS enzymatic activity, with seropositivity for
WNV using recessive and additive genetic models on patient
samples collected from five US centers. We found that the AA
genotype was elevated in WNV-positive individuals regardless of
whether these patients remained asymptomatic or developed
symptomatic disease, including WNF and WNND. We also
observed that homozygosity for the A allele correlated with
increased levels of WNV replication in primary lymphoid tissue
from human donors. Moreover, the results are consistent with the
previously reported identification of the flavivirus resistance locus
flv in mice as a truncation mutation in oas1b [12,13], the ortholog
of human OAS1 [14]. Our data do not confirm the previously
published association of OASL and WNV infection in man.
Together, these data suggest that OAS1 activity modulates early
viral replication, and that decreased OAS1 activity is associated
with increased risk of infection and seroconversion. These data
suggest that carriers of the G allele, which is associated with high
OAS1 activity, may effectively control WNV replication early after
infection in humans through innate mechanisms. Furthermore,
since oas1b in the mouse has been implicated in resistance not only
Figure 4. Ex vivo model of WNV replication in cultured human lymphoid tissue. (A) Blocks of human tonsil tissue were inoculated ex vivo
with WNV. Culture supernatant from WNV-infected and -uninfected tonsil tissue was sampled every third day for 12 days and viral titers assessed by
FFU assay. 27 tissue blocks were used per experimental condition for each donor. The calculated maximal viral titer based on inoculum alone on day
0 is 1500 FFU/ml. Data represent the mean value of duplicate measurements with standard deviation. Note that data were not assessed for three
patients on day 12. (B) Representative WNV immunostaining of WNV-infected (left panel) or donor-matched uninfected lymphoid tissue (right panel)
cultured ex vivo for nine days. Scale bar, 100 mm.
doi:10.1371/journal.ppat.1000321.g004
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PLoS Pathogens | www.plospathogens.org 7 February 2009 | Volume 5 | Issue 2 | e1000321Figure 5. Induction of OAS1 RNA in human lymphoid tissue infected with WNV. Quantitative RT-PCR analysis of OAS1 (A) and IFN-b1 (B)
induction in WNV-infected tissue versus matched uninfected tissue taken at various times post-infection from 12 patients and presented as
means6SEM. Primers used for OAS1 analysis are located in exon 2 and 3 and thus amplify all OAS1 transcripts. (C) OAS1 genotypes were determined
for SNP rs10774671 using ABI SNP genotyping methods. cDNA from uninfected blocks of human tonsil tissue were tested for the presence of OAS1
SNP-dependent splice variants using primers specifically flanking the SNP as previously described [23]. PCR products were resolved on 2% agarose
gel. The presence of the G allele produced an amplicon of 416 bp, while the presence of the A allele gave rise to a 319 bp and 417 bp fragment.
Patient genotypes are denoted above the lane; M, molecular weight marker. (D) RNA was extracted at the indicated times after WNV infection of
tonsil tissues from 12 donors; uninfected tissue RNA from the same donor served as a control at each time point. cDNA generated was used for PCR
using the same primers as described above. Amplicons for the total OAS1 rs10774671-specific transcripts were quantified using densitometric analysis
normalized to b-actin. The mean+/2SEM are shown. (E) The induction of OAS1 rs10774671 A-allele specific RNA from AA homozygous donors was
analyzed separately (n=5). Fold induction is shown as mean+/2SEM. ***p,0.0001; **p,0.005; *p,0.05.
doi:10.1371/journal.ppat.1000321.g005
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be relevant for other medically important neurotropic flaviviruses,
such as Japanese encephalitis virus, Yellow Fever virus, and Tick-
borne encephalitis virus.
There are several limitations to our study. First, like most gene
association studies, the analysis is retrospective. Second, due to a
limitation of sample availability the association of WNV infection
with OAS1 SNP 10774671 was determined only in North
American Caucasians. Third, the epidemiologic data, while
consistent with a role for OAS1 in controlling WNV infection, do
not establish causality versus linkage disequilibrium with an as yet
unidentified causal variant. Importantly though, the variant tested
has been previously associated with OAS function, and is therefore
biologically plausible [23].
Additional work will be needed to delineate the precise
mechanisms by which OAS1 SNP rs10774671 variation may
affect WNV infection. We were able to detect the OAS1 A and G
allele transcripts in uninfected human tonsil tissue as predicted by
donor genotype, and we found that WNV infection was able to
induce total OAS1 RNA in the tissue as well as RNA specific for
the OAS1 A and G alleles. However, additional work will be
needed to determine OAS1 allele-specific activity in tonsil tissue as
a function of WNV infection, and the relative contribution of each
of the OAS1 isoforms present in the tissue. While OAS activity in
human PBMCs has been reported to vary in an OAS1 SNP
rs10774671-dependent manner, with the rank order GG.A-
G.AA, OAS enzymatic activity of purified protein encoded by
OAS1 A and G allele variants has not yet been determined [23].
Furthermore, the mechanism of action of oas1b in mice is not yet
clear, nor is there evidence that oas1b is enzymatically active [16]
or that it functions through activation of RNaseL [15].
Population stratification as a cause of skewed genotypic
frequency is a concern in all gene association studies. Given the
limited availability of genomic DNA from the small samples of
serum available to us from WNV+ subjects, we were unable to
address this issue directly. However, we believe this is unlikely to
confound our results since the five WNV+ groups were from
geographically distinct US populations yet had similar AA
genotypic frequencies ranging from 47.1% to 51.4% with an
average of 49.3%, whereas the two US WNV-negative control
populations that we genotyped, which also were from distinct
geographic regions, had much lower AA genotypic frequencies
(36.7 and 40.6%) that both fell within a narrow range reported in
previously published studies, (36.8–41.1%) [27,28,29]. In partic-
ular, Smyth et al reported an OAS1 SNP rs10774671 AA genotypic
frequency of 41.1% for 4,735 subjects from the 1958 British Birth
Cohort (www.cls.ioe.ac.uk/studies.asp?section=000100020003)
[29]; Fedetz et al reported a frequency of 36.8% for 424
Caucasians from Spain [27]; and the International HapMap
Project reported a frequency of 39% in US Caucasians (n=59;
www.hapmap.org). It is important to note that a fourth published
study, by Field et al., reported an AA genotypic frequency of
49.9% [28]. This anomaly is most likely due to the use of a non-
random population, namely the healthy siblings of diabetics. In
particular, the A allele frequency in non-transmitted alleles of the
parents, which would be expected to have nothing to do with
disease, was 0.61 in this study, which would give an expected
frequency of 0.6160.61=37% for the AA genotype (L. Field,
personal communication), compatible with the frequency found
in all five other control populations. Of note, no difference in
frequency was observed between cases and controls in a
genetically unlinked but related variant in OASL (www.hapmap.
org), where the odds ratio for all genetic models tested was 1.0,
p$0.82.
Animal studies have shown conclusively that the type I IFN
system exerts potent antiviral effects critical for survival from viral
infections, including WNV infection [9,30,33,34]. However, there
is limited evidence in humans supporting a role for endogenous
type I IFN signaling at the level of viral pathogenesis. Our study
suggests a potentially important role of this type I IFN-inducible
pathway at the level of initial infection and containment of virus
during the early phases of natural human infection. Our data show
that WNV infection is less likely to result in seroconversion in
individuals with the GG genotype (higher OAS enzymatic
activity), suggesting that individuals with the AA genotype (lower
enzymatic activity) are less likely to control initial WNV infection
with innate immunity and initiate an adaptive immune response,
signaled by seroconversion.
Genetic variation in OAS1 has been previously associated with
other diseases, including Type I Diabetes, SARS, and Hepatitis C.
The associations in Type I Diabetes and SARS have been
inconsistent in different studies [28,29,35,36]. For Hepatitis C, a
relative of WNV also in the flavivirus family, a polymorphism in
the 39-untranslated region of OAS1 has been associated with
persistent infection [37]. This is particularly relevant since this
polymorphism is in strong linkage disequilibrium with polymor-
phism rs10774671 which we have associated with WNV
seroconversion [23].
Figure 6. WNV replication of cultured human lymphoid tissue ex vivo is OAS1 genotype-dependent. Viral titers measured at each three-
day interval were plotted according to OAS1 splice acceptor site genotype. Data points represent the amount of virus measured at each three-day
interval, and lines indicate the median value. Individuals homozygous for the A allele were compared to AG heterozygotes plus GG homozygotes.
Note that viral titers for three patients were not assessed at day 12.
doi:10.1371/journal.ppat.1000321.g006
OAS1 and Initial Infection with West Nile Virus
PLoS Pathogens | www.plospathogens.org 9 February 2009 | Volume 5 | Issue 2 | e1000321A clinical implication of our results is that pharmacologic
induction of OAS1, which has been shown to occur in response to
IFNa treatment [38,39] could be efficacious in the context of
preventing WNV infection in man. While treatment with IFNa
has been reported to be effective in WNV-infected patients, the
world experience is limited to a small number of scattered case
reports, and treatment failure has also been documented
[40,41,42]. Our data support continued clinical research of IFNa
as a therapeutic option in WNV disease. Finally, our data indicate
that the great majority of risk of symptomatic WNV disease
remains unexplained at the genetic level, and support continued
research into variation in the type I IFN system as a factor
contributing to the heterogeneity of outcome in this disease.
Materials and Methods
Study populations
The study was approved by the Office of Human Subjects
Research of the NIH. Samples of symptomatic WNV-seropositive
patient cases from four US states (AZ, CO, CA, and IL) were
collected as previously described [20,21]. Since the allele
frequency of this SNP varies by race (www.hapmap.org), and
since information about race was not available for all subjects in
the WNV-seropositive patient cases, we analyzed only self-
reporting Caucasians (total n=331 in the 4 US states combined).
Symptomatic WNV-seropositive patients are defined as individu-
als who came to clinical attention with symptoms consistent with
WNV disease (primarily WNF, WNND), where WNV was
confirmed using serological tests. Of the WNV-seropositive
samples received, sufficient DNA from self-reported Caucasian
patients was available for analysis of 345 samples. Genotypes for
both OAS1 and OASL were obtained for 331 symptomatic WNV-
seropositive subjects with an overall genotyping success rate of
95.9%. Serum samples were collected from the following states
and years: 1) Arizona from the 2004 epidemic (n=135); 2)
Colorado from the 2003 epidemic (n=72); 3) California from the
2005 epidemic (n=87); 4) Illinois from the 2005/2006 epidemic
(n=37). Plasma samples from asymptomatic WNV-seropositive
blood donors from the American Red Cross (ARC WNV+) were
collected between 2003–2008. Asymptomatic WNV-seropositive
blood donors (n=170) are defined as Caucasian random blood
donors who tested reactive for WNV nucleic acid twice and were
WNV IgM seropositive who remained asymptomatic for at least 2
weeks post donation as assessed by follow-up questionnaire as
described previously [25].
Two healthy US Caucasian control groups were established: 1)
healthy unrelated US Caucasian random blood donors (RBD)
from the NIH Department of Transfusion Medicine (n=360)
collected under an IRB-approved protocol [20]; and 2) healthy
Caucasian blood donors from the American Red Cross (n=192)
who tested WNV nucleic acid reactive upon initial screen at the
time of blood donation, but were negative for WNV nucleic acid
upon retesting and were also WNV-seronegative for IgM (false
positives). The following information was provided if available:
age, gender, self-reported racial group, date of sample collection,
and CDC-defined clinical presentation at the time of sample
collection: WNF, WNND, and death. For all study samples,
investigators were blinded to unique patient identifiers.
DNA isolation and genotyping
200 ml of serum collected from Arizona, Colorado, California,
and Illinois were thawed for genomic DNA purification using the
QiaAmp 96 DNA Blood Kit according to the manufacturer’s
instructions (Qiagen, Valencia, CA). 250 ml of plasma collected
from test subjects by the American Red Cross was purified using
NucliSENS EasyMAG automated nucleic acid extraction tech-
nology (Biomerieux, Inc). Purified DNA was eluted into 100 mlo f
the recommended buffer and stored at 4uC until further use. DNA
from NIH random blood donors was isolated from peripheral
blood leukocytes as previously described [43]. SNPs were
genotyped using the ABI 7900HT PCR System with TaqMan
primer/probe mix predesigned and validated by ABI
(C___2567433_10 and C__11753831_1_). PCR-RFLP was used
as a second genotyping method for OAS1 SNP rs10774671 as
previously described [27].
Statistical analysis
Contingency tables were utilized to calculate genotypic and
allelic frequency differences between cases and controls by
comparing numbers of expected (Hardy-Weinberg equation) and
observed individuals using chi-square tests of significance to obtain
a two-sided p value using either 1 (262 table) or 2 (362 table)
degrees of freedom. ORs were calculated using a recessive genetic
model (i.e. AA verses AG plus GG for OAS1 and TT versus TC
plus CC for OASL) or the dominant genetic model (i.e. AA plus
AG versus GG for OAS1 and TT plus TC versus CC for OASL)b y
cross tabulation and 95% CI were estimated using the approx-
imation of Woolf (GraphPad Software version 4.0b, San Diego,
CA). The additive model OR values and 95% CI were calculated
using JMP software. Chi-square was used unless otherwise
indicated. ORs and CIs based on the additive model were
estimated using JMP (SAS, version 7). Chi-square goodness-of-fit
statistics were used to compare dominant, recessive, and additive
models. The two-sided unpaired t-test was used to calculate
statistical significance of viral replication after log10 transformation
of the data for each time point and a two-sided paired t-test was
used to calculate significance of gene expression analysis. P values
were considered significant if ,0.05 and the reported values have
not been corrected for multiple comparisons. Linkage disequilib-
rium of OAS1 SNPs and resultant haplotypes were examined using
Haploview 4.0 (available at www.broad.mit.edu/mpg/haploview/
index) using previously obtained data from the International
HapMap project (www.hapmap.org) on the CEU panel using
release 21 data.
Infection of human lymphoid tissue ex vivo
Human tonsils from routine tonsillectomy performed at the
Children’s Hospital National Medical Center in Washington, DC
were collected under an Institutional Review Board-approved
protocol from NICHD within a few hours after surgery. The mean
age of the children used in this study was 563. Tonsils were
dissected in blocks of approximately 2 mm. 9 tissue blocks per well
in triplicate wells per condition were placed on top of collagen
sponge gels floating in six-well plates as previously described [44].
All 27 tissue blocks from each donor were then individually
inoculated with 5 ml containing 500 FFU WNV strain NY99, or
left uninfected. We assessed productive WNV infection by
measuring FFU as described above in culture medium pooled
from 27 blocks during the previous 3 days between successive
media changes. FFU at each time point represent the cumulative
total of infectious virions produced. Coefficient of variation for
each donor and each time point was calculated to be 13.3%. All
tonsil donors were analyzed for the CCR5D32 mutation as
previously described [20] and found to be wild type at this allele.
Viral Titers
Confluent Vero cells were grown in a 12 well plate in OptiPro
SFM (Invitrogen) with 2% FBS (Hyclone) and 50 mg/ml
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diluted and incubated on the cells for 1 hour at 37uC prior to
overlaying with 2 ml Opti-MEM (Invitrogen) with 8 g/L meth-
ylcellulose (Sigma), 2% FBS and 50 mg/ml gentamicin. Plates
were incubated for 2 days at 37uC, then washed 3 times with PBS.
500 ml of diluted anti-WNV anti-sera/well (HMAF, ATCC #VR-
82) was incubated for 1 hour at 37uC. Plates were then washed 3
times and 500 ml of diluted (1:10) anti-mouse/anti-rabbit HRP
labeled polymer (DAKO Cytomation) was added. Cells were
incubated for 1 hour at 37uC, washed 3 times and focus forming
units (FFU) of WNV were visualized by addition of 1 ml
diaminobenzidine (DAB) mixture (4.5 mg DAB (Sigma) /10 ml
PBS+4.5 ml 30% H202 /10 ml). Viral titers are expressed as FFU/
ml.
Real-time PCR
RNA was extracted from lymphoid tissue using the RNeasy
Tissue kit according to manufacturer’s protocol (Qiagen). Reverse
transcription was performed using Superscript III first strand
synthesis Supermix (Invitrogen) with random hexamers. OAS1
(Hs00242943_m1), IFNb1 (Hs00277188_s1) and GAPDH
(Hs00266705_g1) primer/probe sets were obtained from ABI
and cycled on an ABI 7900HT PCR System. Each sample was
normalized to GAPDH and fold change in infected samples were
compared to uninfected donor-matched samples.
Immunohistochemistry
4–5 mm sections of paraffin-embedded slides were stained with
anti-WNV hyperimmune mouse ascites fluid (HMAF, ATCC
#VR-82) diluted 1:100 in antibody diluent, background reducing
agent (DAKO Cytomation). After incubation with anti-mouse
polymer-horse radish peroxidase (DAKO Cytomation), slides were
developed with streptavidin and diaminobenzidine liquid (DAKO
Cytomation) and counterstained with hematoxylin.
Detection of OAS1 splice variants
Tissues from 12 tonsil donor samples were tested for OAS1
SNP-specific mRNA. cDNA from uninfected and infected donor-
matched samples for each time point amplified by PCR as
previously described [23]. Briefly, primers were designed to flank
the splice acceptor site (F-ggcggaccctacaggaaact; R-acaccagctcact-
gaggagc). The presence of a G allele resulted in a 416 bp
amplicon, while the presence of the A allele resulted in 319 bp and
417 bp fragments. PCR products were resolved on a 2% agarose
gel, visualized using ethidium bromide, and quantitated by
densitometry normalized to b-actin using Image J software version
1.386. Fold change was calculated by comparing normalized
WNV-infected measurements to normalized uninfected measure-
ments for each time point for each donor.
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